| budesonide/formoterol / Generic mfg. |
2020-001713-20: Efficacy and safety of budesonide/formoterol versus terbutaline nebulization to treat children having an asthma attack Efficacité et sécurité du budenoside/formoterol par rapport à la terbutaline pour traiter les enfants ayant une crise d'asthme |
|
|
| Not yet recruiting | 3 | 102 | Europe | , Inhalation powder, pre-dispensed, Bricanyl, Symbicort | Centre Hospitalier Intercommunal de Créteil, Astrazeneca | moderate asthma exacerbation exacerbation modérée d'asthme, asthma crisis crise d'asthme, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
ACTRN12622001217796: A Randomised Controlled Trial of the efficacy and safety of an Inhaled Corticosteroid and Long Acting Beta Agonist maintenance and/or reliever therapy versus standard maintenance with separate reliever therapy in children with mild, moderate and severe asthma. |
|
|
| Recruiting | 3 | 400 | | | Medical Research Institute of New Zealand, AstraZeneca Ltd | Asthma | | | | |
| Completed | 3 | 48 | US | budesonide/formoterol, Symbicort, fluticasone/salmeterol, Advair Diskus, albuterol, Ventolin | AstraZeneca | Asthma | | 08/03 | | |
NCT00651651: Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5 |
|
|
| Completed | 3 | 450 | US | budesonide/formoterol, Symbicort, budesonide, formoterol | AstraZeneca | Asthma | | 09/03 | | |
| Completed | 3 | 48 | US | budesonide/formoterol (Symbicort), Symbicort, fluticasone/salmeterol (Advair Diskus), Advair Diskus, albuterol (Ventolin), Ventolin | AstraZeneca | Asthma | | 09/03 | | |
NCT00646529: Long-Term Safety of Symbicort in Asthmatic Children - SAPLING |
|
|
| Completed | 3 | 175 | US | budesonide/formoterol (Symbicort), Symbicort, budesonide (Pulmicort), Pulmicort | AstraZeneca | Asthma | | 10/03 | | |
| Completed | 3 | 405 | US | budesonide/formoterol, Symbicort, budesonide, formoterol | AstraZeneca | Asthma | | 10/03 | | |
NCT00652002: Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5 |
|
|
| Completed | 3 | 450 | US | budesonide/formoterol, Symbicort, budesonide, formoterol | AstraZeneca | Asthma | | 01/04 | | |
NCT00652392: Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM |
|
|
| Completed | 3 | 750 | US | budesonide/formoterol, Symbicort, budesonide and placebo | AstraZeneca | Asthma | | 06/04 | | |
NCT00646321: Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT |
|
|
| Completed | 3 | 540 | US | budesonide/formoterol (Symbicort), Symbicort, budesonide | AstraZeneca | Asthma | | 08/04 | | |
NCT00651768: Titratable Dosing in Moderate to Severe Asthmatics |
|
|
| Completed | 3 | 570 | US | budesonide/formoterol, Symbicort, Symbicort pMDI + budesonide HFA pMDI | AstraZeneca | Asthma | | 01/05 | | |
| Completed | 3 | 1200 | US | budesonide/formoterol (Symbicort), Symbicort, fluticasone/salmeterol (Advair), Advair | AstraZeneca | Asthma | | 01/05 | | |
| Completed | 3 | 615 | US | budesonide/formoterol (Symbicort), Symbicort | AstraZeneca | Mild or Moderate Asthma | | 02/05 | | |
NCT00413387: Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®) |
|
|
| Completed | 3 | 219 | Europe, RoW | beclomethasone dipropionate plus formoterol fumarate combination, budesonide plus formoterol combination | Chiesi Farmaceutici S.p.A. | Bronchial Asthma | 08/05 | 10/05 | | |
NCT00238784: SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults |
|
|
| Completed | 3 | 1300 | Canada | Budesonide/formoterol Turbuhaler | AstraZeneca | Asthma | 10/05 | 10/05 | | |
SYMPHONIE, NCT00259792: - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults |
|
|
| Completed | 3 | 1000 | Europe | Budesonide/formoterol Turbuhaler, Symbicort | AstraZeneca | Asthma | | 01/06 | | |
| Completed | 3 | 16 | Europe | formoterol, budesonide/formoterol | AstraZeneca | Asthma | | 05/06 | | |
NCT00252863: DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults |
|
|
| Completed | 3 | 1600 | Europe | Symbicort, used twice daily (b.i.d) and as needed (prn), Budesonide Turbuhaler 200 µg, Fluticasone Discus 250 µg, Formoterol Turbuhaler 4.5 µg, Terbutaline Turbuhaler 0.5 mg, Salbutamol pressurized metered dose inhaler (pMDI) 100 µg, Salmeterol Discus 50 µg, Budesonide/Formoterol Turbuhaler 160/4.5 µg, Fluticasone/Salmeterol Discus 250/50 µg, Fluticasone/Salmeterol Discus 500/50 µg, Theophylline 200 mg, Theophylline 300 mg, Singulair 10 mg | AstraZeneca | Asthma | | 05/06 | | |
NCT00242775 / 2004-004905-11: Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg |
|
|
| Completed | 3 | 2100 | Canada, Europe, RoW | Budesonide/formoterol Turbuhaler, Symbicort, Salmeterol/fluticasone Diskus | AstraZeneca | Asthma | | 05/06 | | |
| Completed | 3 | 1000 | Europe | Budesonide/formoterol, Symbicort | AstraZeneca | Asthma | | 08/06 | | |
NCT00235911: Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting |
|
|
| Completed | 3 | 100 | Europe | budesonide/formoterol Turbuhaler | AstraZeneca | Asthma | 10/06 | 12/06 | | |
NCT00252785: Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients |
|
|
| Completed | 3 | 340 | Japan | Budesonide/Formoterol, Symbicort, Budesonide, Theophylline | AstraZeneca | Asthma | | 11/06 | | |
| Completed | 3 | 1000 | Europe, RoW | Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy, Symbicort | AstraZeneca | Asthma | | 12/06 | | |
| Completed | 3 | 550 | Europe | Budesonide/formoterol, Symbicort® Turbohaler® | AstraZeneca | Asthma | | 12/06 | | |
NCT00255255: Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma |
|
|
| Completed | 3 | 120 | Japan | Budesonide/Formoterol, Symbicort | AstraZeneca | Asthma | 12/06 | 06/07 | | |
NCT00244608 / 2004-004042-41: A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler® |
|
|
| Completed | 3 | 100 | Europe | Budesonide/Formoterol Turbuhaler, Symbicort, Budesonide Turbuhaler (Pulmicort), Terbutaline Turbuhaler | AstraZeneca | Asthma | | 03/07 | | |
NCT00259766: SHARE - Symbicort and Health Economics in a Real Life Evaluation |
|
|
| Completed | 3 | 1970 | Europe | Budesonide, Symbicort, Formoterol, Terbutaline | AstraZeneca | Asthma | | 05/07 | | |
| Completed | 3 | 600 | Canada | Budesonide/formoterol, Symbicort | AstraZeneca | Asthma | | 05/07 | | |
NCT00449527: A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects |
|
|
| Completed | 3 | 123 | US | Budesonide/formoterol pMDI, Symbicort, Budesonide HFA pMDI | AstraZeneca | Asthma | | 08/07 | | |
NCT00449501: A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects |
|
|
| Completed | 3 | 134 | US | Budesonide/formoterol pMDI, Symbicort, Budesonide HFA pMDI | AstraZeneca | Asthma | | 11/07 | | |
| Completed | 3 | 107 | Europe, RoW | Budesonide/formoterol pMDI 40/2.25ug + spacer, Budesonide/formoterol pMDI 40/2.25 ug | AstraZeneca | Asthma | 02/08 | 02/08 | | |
| Completed | 3 | 742 | Europe | Symbicort Turbuhaler, Symbicort pMDI, Pulmicort Turbuhaler | AstraZeneca | Bronchial Asthma | 04/08 | 04/08 | | |
NCT00419757: An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma |
|
|
| Completed | 3 | 558 | US | Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI | AstraZeneca | Asthma | 06/08 | 06/08 | | |
PASSION, NCT00628758: A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma |
|
|
| Completed | 3 | 430 | RoW | Symbicort TBH - Turbuhaler, beta-II-agonist, inhale steroid, Astmerol inh 25 mcg/dosage, 60-120 dosage, Astmerol maksihaler 50 mcg/dosage, 28-60 dosage, Serevent diskus 50 mcg/dosage, 60 dosage, Serevent inh 25 mcg/dosage, 60 dosage, Foradil inh kap 12 mcg/dosage, 60 caps, Foradil inh 12 mcg/dosage, 50-100 dosage, Foradil combi 200 mcg, Foradil combi 400 mcg, Oxis turbuhaler 4.5-9 mcg/dosage, 60 dosage, Ventofor 12mg/60 inh.caps, Seretide disc 100-250-500 mcg/dosage 60 dosage, Symbicort 160/4.5 mcg/60-120 dosage, 320/9mcg/60 dosage | AstraZeneca | Asthma | 09/08 | 09/08 | | |
| Terminated | 3 | 654 | Europe | Symbicort (budesonide/formoterol) Turbuhaler, Conventional treatment | AstraZeneca | Asthma, Bronchial | | 10/08 | | |
| Completed | 3 | | Canada | budesonide and budesonide/formoterol | Laval University, AstraZeneca | Asthma | | | | |
NCT00837967: Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients |
|
|
| Completed | 3 | 25 | Japan | Symbicort Turbuhaler, Terbutaline Turbuhaler | AstraZeneca | Asthma | 07/09 | 07/09 | | |
NCT00419952: A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma. |
|
|
| Completed | 3 | 742 | US | Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI | AstraZeneca | Asthma | 11/09 | 11/09 | | |
NCT01099722 / 2009-017223-25: Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma |
|
|
| Completed | 3 | 261 | Europe, RoW | Flutiform, Symbicort Turbohaler | Mundipharma Research Limited | Asthma | 11/10 | 07/11 | | |
| Completed | 3 | 2091 | Japan, Europe, RoW | Symbicort Turbuhaler, Terbutaline Turbuhaler | AstraZeneca | Asthma | 02/11 | 02/11 | | |
| Completed | 3 | 450 | | one inhalation of Pulmicort Turbuhaler 200 ug/inhalation ;Oxis Turbuhaler 4.5 ug/inhalation with symptom-driving ;Symbicort Turbuhaler 160/4.5 ug/inhalation with symptom-driving | 1st Affiliated Hospital of SYSU; 2nd and 3rd Affiliated Hospital of SYSU, 1st Affiliated Hospital of SYSU | mild asthma | | | | |
| Completed | 3 | 214 | US, Europe, RoW | Symbicort, Budesonide | AstraZeneca | Asthma | 08/12 | 08/12 | | |
| Completed | 3 | 605 | Europe, RoW | Budesonide/Formoterol SPIROMAX®, SYMBICORT® TURBOHALER®, SYMBICORT placebo, SPIROMAX Placebo | Teva Branded Pharmaceutical Products R&D, Inc. | Asthma | 03/14 | 03/14 | | |
ELIOT, NCT02062463 / 2013-004630-14: Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma |
|
|
| Completed | 3 | 485 | Europe | Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX, SPIROMAX®, SYMBICORT TURBOHALER budesonide and formoterol fumarate, SYMBICORT®, TURBOHALER® | Teva Branded Pharmaceutical Products R&D, Inc. | Asthma | 03/15 | 03/15 | | |
| Completed | 3 | 72 | Europe | Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh, Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh, Symbicort Turbuhaler 320/9 ug/inhalation 4 inh, Symbicort Turbuhaler 320/9 ug/inhalation 1inh, Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh, Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh, Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh, Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh | Orion Corporation, Orion Pharma | Asthma | 06/15 | 06/15 | | |
| Completed | 3 | 12460 | Europe, US, RoW | Symbicort pMDI, budesonide pMDI | AstraZeneca | Asthma | 10/15 | 10/15 | | |
2008-004833-70: A phase III, randomized, parallel group, open study to compare the therapeutic efficacy and safety of SMB BUDESONIDE-SALMETEROL DPI capsule 150/25μg BID delivered by the AXAHALER® versus SYMBICORT® TURBUHALER® 200/12μg BID over 12 weeks in moderate to severe persistent asthmatic patients. |
|
|
| Completed | 3 | 68 | Europe | SMB BUDESONIDE-SALMETEROL DPI 150/25µg, SYMBICORT® TURBUHALER® 100/6µg, PULMICORT® TURBUHALER® 200 µg, SYMBICORT® TURBUHALER® 100/6µg, PULMICORT® TURBUHALER® 200 µg | Laboratoires SMB S.A. | Patients with moderate to severe persistent asthma. | | 08/09 | | |
2010-019082-29: A double-blind, double-dummy, randomized, placebo- and active-controlled, three-way crossover study to evaluate the effect of Budesonide/Formoterol Spiromax® 80/4.5 mcg Inhalation Powder and Symbicort® Turbohaler® 100/6 mcg on the short-term lower leg growth rate in prepubescent children with persistent asthma. |
|
|
| Completed | 3 | 78 | Europe | Budesonide/Formoterol Spiromax® 80/4.5 mcg Inhalation Powder, BF Spiromax, Symbicort® Turbohaler® 80/4,5 Mikrogramm/Dosis Pulver zur Inhalation, Symbicort® Turbohaler® 80/4,5 Mikrogramm/Dosis Pulver zur Inhalation | Teva Branded Pharmaceutical Products R&D, Inc. | Short term lower leg growth rate in prepubescent children with persistent asthma. | | | | |
CHASE 3, NCT02091986 / 2013-005293-22: A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg |
|
|
| Completed | 3 | 882 | US, Europe, RoW | Symbicort pMDI, Budesonide pMDI, Active comparator | AstraZeneca | Asthma | 04/16 | 04/16 | | |
2015-002384-42: Randomised Controlled Trial of the efficacy and safety of an ICS (Inhaled Corticosteroid)/LABA (long-acting beta agonist) reliever therapy regimen in asthma. |
|
|
| Ongoing | 3 | 675 | Europe | Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, inhalation powder, Pulmicort® Turbohaler® 200, Ventolin® Evohaler® 100 micrograms, N/A, Inhalation powder, Pressurised inhalation, Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, inhalation powder, Pulmicort® Turbohaler® 200, Ventolin Inh. CFC free 100 micrograms | Medical Research Institute of New Zealand, Astra Zeneca | Asthma., Asthma., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT02725242: Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down Asthma |
|
|
| Completed | 3 | 77 | RoW | Budesonide/formoterol (160/4.5 μg/d), Symbicort Turbuhaler (160/4.5 μg/d), Budesonide (400μg/d), Giona Easyhaler | Hat Yai Medical Education Center | Asthma | 12/16 | 12/16 | | |
2014-004564-38: A study to compare how easily patients with breathing conditions (asthma, chronic obstructive pulmonary disease (COPD) and asthma COPD overlap syndrome) can use two different types of inhaler. |
|
|
| Completed | 3 | 368 | Europe | Fluticasone/formoterol BAI 50/5 µg, Fluticasone/formoterol BAI 125/5 µg, K-haler, Pressurised inhalation, suspension, Inhalation powder, flutiform® 50 micrograms / 5 micrograms per actuation pressurised inhalation, suspension, flutiform® 125 micrograms / 5 micrograms per actuation pressurised inhalation, suspension, Symbicort® Turbohaler® 100 micrograms/6 micrograms, Inhalation powder, Symbicort® Turbohaler® 200 micrograms/6 micrograms, Inhalation powder | Mundipharma Research Limited, Mundipharma Research Limited | Asthma, Asthma-COPD Overlap Syndrome (ACOS) and Chronic Obstructive Pulmonary Disease., Long term breathing problems (Asthma, Chronic Obstructive Pulmonary Disease and a combination of the two), Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2014-000551-81: Efficacy study to evaluate fluticasone furoate /vilanterol Inhalation Powder delivered once daily via the Dry Powder Inhaler Ellipta™ compared with usual ICS/LABA maintenance therapy delivered by Dry Powder Inhaler in subjects with Persistent Asthma |
|
|
| Completed | 3 | 422 | Europe | Inhalation powder, pre-dispensed, Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed, Relvar Ellipta 184 microgrammes/22 microgrammes, Viani 50 μg/250 μg Diskus, Viani forte 50 μg/500 μg Diskus, Symbicort Turbohaler 160/4,5 Mikrogramm/Dosis Pulver zur Inhalation, Symbicort Turbohaler 320/9 Mikrogramm/Dosis Pulver zur Inhalation | GlaxoSmithKline Research & Development Limited, GlaxoSmithKline | Subject with persistent asthma, Persistent asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Completed | 3 | 3850 | Europe, Canada, RoW | budesonide/formoterol 'as needed' + budesonide placebo bid, terbutaline 'as needed' + placebo budesonide bid, budesonide bid + terbutaline 'as needed' | AstraZeneca | Asthma | 08/17 | 08/17 | | |
| Completed | 3 | 4215 | Europe, RoW | budesonide/formoterol 'as needed' + budesonide placebo bid, budesonode bid + terbutaline 'as needed' | AstraZeneca | Asthma | 08/17 | 08/17 | | |
ACTRN12615000999538: Randomised Controlled Trial of the efficacy and safety of an Inhaled Corticosteroid / Long Acting Beta Agonist reliever therapy regimen in asthma |
|
|
| Completed | 3 | 675 | | | Medical Research Institute of New Zealand, AstraZeneca AB | Asthma | | | | |
ACTRN12616000377437: Randomised Controlled Trial of the efficacy and safety of an Inhaled Corticosteroid and Long Acting Beta Agonist reliever therapy regimen in asthma
|
|
|
| Completed | 3 | 890 | | | Medical Research Institute of New Zealand , Health Research Council of New Zealand | Asthma | | | | |
NCT03015259: Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients |
|
|
| Completed | 3 | 1762 | US | Budesonide/Formoterol fumarate dihydrate, Generic Budesonide/Formoterol fumarate dihydrate, Symbicort, Placebo | Kindeva Drug Delivery | Asthma | 02/18 | 02/18 | | |
NCT02495168: Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants |
|
|
| Completed | 3 | 1714 | US | Generic Budesonide/Formoterol Fumarate Dihydrate, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate), Symbicort Turbohaler®, Placebo | Actavis Inc., Teva Pharmaceuticals USA | Asthma | 05/18 | 05/18 | | |
NAP, NCT04607629: An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma |
|
|
| Completed | 3 | 192 | RoW | Genolar® + Symbicort®, omalizumab & (budesonide+formoterol), GNR-044 & (budesonide+formoterol), Xolair® + Symbicort® | AO GENERIUM | Bronchial Asthma | 04/19 | 12/19 | | |
ACTRN12619001083189: A study comparing the changes in lung function following the use of salbutamol and symbicort in adults with asthma |
|
|
| Completed | 3 | 39 | | | Medical Research Institute of New Zealand, AstraZeneca | Asthma | | | | |
NCT03468790: Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma. |
|
|
| Completed | 3 | 393 | RoW | CMAB007, recombinant humanized anti-IgE monoclonal antibody, Symbicort, budesonide and formoterol fumarate powder for inhalation, Seretide, salmeterol xinafoate and fluticasone propionate, Ventolin, Salbutamol sulphate aerosol, placebo | Shanghai Biomabs Pharmaceutical Co., Ltd. | Asthma, Allergic | 01/21 | 03/21 | | |
ACTRN12619001387112: A study comparing the speed of airway dilatation following a single dose of salbutamol versus a single dose of symbicort in adult asthmatics |
|
|
| Terminated | 3 | 50 | | | The Medical Research Institute of New Zealand, The Medical Research Institute of New Zealand | asthma , Bronchodilation | | | | |
ASTHMAFAST, NCT04705727: Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation |
|
|
| Terminated | 3 | 102 | Europe | Budesonide Formoterol Drug Combination, nebulisation of terbutaline | Centre Hospitalier Intercommunal Creteil, AstraZeneca | Asthma in Children | 09/21 | 06/23 | | |
NCT04215848: As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period |
|
|
| Completed | 3 | 31 | RoW | Budesonide/Formoterol Fumarate 160 MCG-4.5 MCG Inhalation Powder, Symbicort Turbuhaler (160/4.5 ug), Budesonide 200Mcg Inhalation Powder, Pulmicort Turbuhaler (200 ug) | Hat Yai Medical Education Center | Asthma | 10/21 | 05/22 | | |
NCT05322707: BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient |
|
|
| Completed | 3 | 1485 | US | Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg, Test product, Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol, RLD, Placebo, Placebo for Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg | Cipla Ltd. | Asthma | 08/23 | 08/23 | | |
VATHOS, NCT05202262 / 2021-002026-24: A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma |
|
|
| Recruiting | 3 | 630 | Europe, Canada, Japan, US, RoW | BFF MDI 320/9.6 μg, BFF, BFF MDI 160/9.6 μg, BD MDI 320 μg, BD, Open-label Symbicort TBH 320/9 μg, Symbicort TBH | AstraZeneca | Asthma | 03/25 | 03/25 | | |
ARRIVAL, NCT06473779: Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. |
|
|
| Not yet recruiting | 3 | 300 | NA | Tezepelumab, TEZSPIRE®, Budesonide/formoterol, SYMBICORT® pMDI, Albuterol/budesonide (AIRSUPRA®), AIRSUPRA®, Mannitol, ARIDOL®, Salbutamol, Sabumalin, albuterol, ventolin HFA, Proair HFA, Proventil HFA | AstraZeneca, Fortrea | Severe Asthma | 06/27 | 06/27 | | |
| Recruiting | 3 | 2200 | Europe, Canada, Japan, US, RoW | BGF MDI 320/28.8/9.6 μg, BGF, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF, BFF pMDI 320/9 μg, Symbicort® | AstraZeneca | Asthma | 03/25 | 03/25 | | |
| Recruiting | 3 | 2200 | Europe, US, RoW | BGF MDI 320/28.8/9.6 μg, BGF, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF, BFF pMDI 320/9 μg, Symbicort® | AstraZeneca | Asthma | 03/25 | 03/25 | | |
